The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Improved early prediction of individual prognosis for patients with mCRC: Joint modeling of tumor shrinkage with volume data for PFS and OS.
Ulrich Robert Mansmann
Research Funding - Merck KGaA
Other Remuneration - Merck KGaA
Ruediger Paul Laubender
Honoraria - Merck KGaA
Research Funding - Merck KGaA
Other Remuneration - Merck KGaA
Ute Sartorius
Employment or Leadership Position - Merck KGaA
Clemens Albrecht Giessen
Other Remuneration - Roche
Anno Graser
No relevant relationships to disclose
Volker Heinemann
Consultant or Advisory Role - Merck KGaA; Roche; Sanofi
Honoraria - Merck KGaA; Roche; Sanofi
Research Funding - Merck KGaA
Expert Testimony - Merck KGaA; Roche
Other Remuneration - Merck KGaA; Roche